These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36294464)

  • 21. Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.
    Wakui M; Fujimori Y; Katagiri H; Nakamura S; Kondo Y; Kuroda Y; Nakagawa T; Shimizu N; Murata M
    J Clin Pathol; 2019 Mar; 72(3):244-250. PubMed ID: 30518630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
    Adamkewicz JI; Chen DC; Paz-Priel I
    Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
    Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K
    Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.
    Nakajima Y; Nogami K; Yada K; Furukawa S; Noguchi-Sasaki M; Hirata M; Shima M
    Thromb Haemost; 2020 Jun; 120(6):968-976. PubMed ID: 32384547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
    Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
    Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coagulation Status Using Clot Wave Analysis in Patients With Prolonged Immobilization.
    Iberahim S; Muhamat Yusoff R; Mohd Noor NH; Hassan R; Ramli NN; Bahar R; Zulkafli Z; Wan Ab Rahman WS; Ab Ghani AS
    Cureus; 2024 Jan; 16(1):e51483. PubMed ID: 38304638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
    Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
    Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
    Bowyer AE; Maclean RM; Kitchen S
    Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.
    Atsou S; Schellenberg C; Lagrange J; Lacolley P; Lenting PJ; Denis CV; Christophe OD; Regnault V
    J Thromb Haemost; 2024 Jan; 22(1):112-125. PubMed ID: 37776978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.
    Takeyama M; Ozu N; Kasama S; Kasahara M; Matsumoto M; Shima M; Nogami K
    BMJ Open; 2023 Jul; 13(7):e072565. PubMed ID: 37429679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis.
    Mizumachi K; Tsumura Y; Nakajima Y; Koh K; Nogami K
    Int J Hematol; 2021 Jun; 113(6):930-935. PubMed ID: 33566316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Hemodilution on Clot Waveform Analysis Parameters, Clotting Factors, and Thrombin Generation Assays in a Dilutional Model Based on Analysis of 11 Healthy Male Blood Donors.
    Ichikawa J; Okazaki R; Fukuda T; Yoon D; Komori M
    Med Sci Monit; 2022 Oct; 28():e937368. PubMed ID: 36225091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on the Clot Waveform Analysis.
    Wada H; Matsumoto T; Ohishi K; Shiraki K; Shimaoka M
    Clin Appl Thromb Hemost; 2020; 26():1076029620912027. PubMed ID: 32862666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
    Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
    Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT-clot waveform analysis.
    Gupta D; Arya V; Dass J; Gupta N; Kalra M; Sachdeva A; Kotwal J
    Blood Res; 2024 May; 59(1):19. PubMed ID: 38743166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype.
    Milos M; Coen Herak D; Mahmoud Hourani Soutari N; Pavic J; Zupancic-Salek S; Zadro R; Antovic JP
    Int J Lab Hematol; 2021 Apr; 43(2):273-280. PubMed ID: 32964648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.